

# Bianca L Artiaga

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4556164/publications.pdf>

Version: 2024-02-01

9  
papers

239  
citations

1163117

8  
h-index

1474206

9  
g-index

9  
all docs

9  
docs citations

9  
times ranked

463  
citing authors

#	ARTICLE	IF	CITATIONS
1	Unaltered influenza disease outcomes in swine prophylactically treated with $\hat{1}\pm$ -galactosylceramide. <i>Developmental and Comparative Immunology</i> , 2021, 114, 103843.	2.3	3
2	Modulation of Immune Responses to Influenza A Virus Vaccines by Natural Killer T Cells. <i>Frontiers in Immunology</i> , 2020, 11, 2172.	4.8	13
3	Susceptibility of swine cells and domestic pigs to SARS-CoV-2. <i>Emerging Microbes and Infections</i> , 2020, 9, 2278-2288.	6.5	84
4	Next Generation Sequencing of the Pig $\hat{1}\pm\hat{1}^2$ TCR Repertoire Identifies the Porcine Invariant NKT Cell Receptor. <i>Journal of Immunology</i> , 2019, 202, 1981-1991.	0.8	15
5	Characterizing porcine invariant natural killer T cells: A comparative study with NK cells and T cells. <i>Developmental and Comparative Immunology</i> , 2017, 76, 343-351.	2.3	13
6	Rapid control of pandemic H1N1 influenza by targeting NKT-cells. <i>Scientific Reports</i> , 2016, 6, 37999.	3.3	23
7	$\hat{1}\pm$ -Galactosylceramide protects swine against influenza infection when administered as a vaccine adjuvant. <i>Scientific Reports</i> , 2016, 6, 23593.	3.3	39
8	Targeted disruption of CD1d prevents NKT cell development in pigs. <i>Mammalian Genome</i> , 2015, 26, 264-270.	2.2	20
9	Adjuvant effects of therapeutic glycolipids administered to a cohort of NKT cell-diverse pigs. <i>Veterinary Immunology and Immunopathology</i> , 2014, 162, 1-13.	1.2	29